19 March 2019 - Roche Canada today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance for a Letter of Intent regarding Ocrevus (ocrelizumab) for the first-line treatment of adult patients with relapsing remitting multiple sclerosis with active disease (defined by clinical and imaging features), and for the management of adult patients with early primary progressive multiple sclerosis.

The pan-Canadian Pharmaceutical Alliance is a body set up by the provinces and territories to jointly negotiate terms of public drug plan listings with pharmaceutical companies.

Thirteen of 16 jurisdictions signed on to the pCPA Letter of Intent to list Ocrevus, including: Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia, New Brunswick, Prince Edward Island, Newfoundland & Labrador, Yukon, Non-Insured Health Benefits (NIHB), Correctional Services Canada (CSC), and Veterans Affairs Canada (VAC). Roche Canada will continue to work across the country with the remaining jurisdictions to ensure public funding is available for all eligible patients.

Read Roche press release